Formulary Watch |

All News - Page 7

Brent Eberle: “Not all Cost-Plus is Created Equal"
Brent Eberle: “Not all Cost-Plus is Created Equal"
Brent Eberle: “Not all Cost-Plus is Created Equal"
January 10, 2024
Clients are cautious about how the cost in “cost-plus” programs is determined, how rebates factor in and the benchmarks used, says Navitus’s Brent Eberle.
CVS Caremark to Remove Branded Humira from Formularies
CVS Caremark to Remove Branded Humira from Formularies
CVS Caremark to Remove Branded Humira from Formularies
January 4, 2024
CVS Caremark has entered into an agreement with AbbVie, the manufacturer of Humira, to supply Cordavis with Humira to develop a cobranded product. Cordavis is a CVS company developing private label therapies.
luchschenF-stock.adobe.com
UCB Launches Zilbrysq for Generalized Myasthenia Gravis
UCB Launches Zilbrysq for Generalized Myasthenia Gravis
January 3, 2024
Zilbrysq has a list price $1,047.19 for a 23 mg syringe. It is UCB’s second treatment for patients with myasthenia gravis.
 peterschreiber.media-stock.adobe.com
PBM Ventegra Includes Avastin Biosimilar on Formulary
PBM Ventegra Includes Avastin Biosimilar on Formulary
December 15, 2023
Additionally, the FDA has approved Avzivi — the fifth biosimilar that references the cancer drug Avastin.
© 2024 MJH Life Sciences

All rights reserved.